• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combined TACE and sorafenib for HCC treatment.

作者信息

Hindson Jordan

机构信息

Nature Reviews Gastroenterology & Hepatology, .

出版信息

Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):66. doi: 10.1038/s41575-020-0265-0.

DOI:10.1038/s41575-020-0265-0
PMID:31919475
Abstract
摘要

相似文献

1
Combined TACE and sorafenib for HCC treatment.肝动脉化疗栓塞术（TACE）联合索拉非尼治疗肝癌。
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):66. doi: 10.1038/s41575-020-0265-0.
2
Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.索拉非尼联合经动脉化疗栓塞治疗BCLC B期肝细胞癌的总生存期：倾向评分分析
Int J Clin Pharmacol Ther. 2017 Jun;55(6):498-508. doi: 10.5414/CP202787.
3
[Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].经动脉化疗栓塞联合碘-125粒子植入与索拉非尼治疗门静脉癌栓型肝细胞癌的疗效比较
Zhonghua Gan Zang Bing Za Zhi. 2018 Apr 20;26(4):298-304. doi: 10.3760/cma.j.issn.1007-3418.2018.04.013.
4
Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.微血管侵犯作为索拉非尼联合经肝动脉化疗栓塞治疗复发性中期肝细胞癌疗效预测因子的研究
Radiology. 2019 Jul;292(1):237-247. doi: 10.1148/radiol.2019181818. Epub 2019 May 28.
5
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.使用FT率评估索拉非尼对肝细胞癌患者总生存期的疗效：一种设计的指标。
Adv Ther. 2017 May;34(5):1097-1108. doi: 10.1007/s12325-017-0524-9. Epub 2017 Apr 7.
6
Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study.肝癌经动脉化疗栓塞术（TACE）单独或联合索拉非尼治疗后肿瘤相关血管变化的比较分析：一项回顾性研究
Oncol Lett. 2018 Sep;16(3):3690-3698. doi: 10.3892/ol.2018.9055. Epub 2018 Jul 2.
7
Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.现实环境中肝细胞癌非根治性或姑息性治疗的成本效益分析。
PLoS One. 2017 Oct 10;12(10):e0185198. doi: 10.1371/journal.pone.0185198. eCollection 2017.
8
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.索拉非尼或安慰剂联合载多柔比星微球 TACE 治疗中晚期 HCC：SPACE 试验。
J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.
9
Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.索拉非尼联合经动脉化疗栓塞术可提高肿瘤直径超过10厘米的肝细胞癌患者的生存率：一项单中心回顾性研究。
J BUON. 2017 Jan-Feb;22(1):150-156.
10
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.载药微球 TACE（DSM-TACE）二线治疗索拉非尼拒用或不耐受的 HCC 患者。
Eur Radiol. 2019 Mar;29(3):1285-1292. doi: 10.1007/s00330-018-5692-8. Epub 2018 Aug 31.

引用本文的文献

1
Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis.靶向治疗策略作为肥胖诱导性脂肪性肝炎的替代和可持续治疗选择。
Rev Endocr Metab Disord. 2025 Jun 25. doi: 10.1007/s11154-025-09980-7.
2
High Mobility Group Box 1 Is Potential Target Therapy for Inhibiting Metastasis and Enhancing Drug Sensitivity of Hepatocellular Carcinoma.高迁移率族蛋白盒1是抑制肝细胞癌转移和增强其药物敏感性的潜在靶向治疗靶点。
Int J Mol Sci. 2025 Apr 8;26(8):3491. doi: 10.3390/ijms26083491.
3
Construction of a prognostic model based on disulfidptosis-related genes and identification of CCNA2 as a novel biomarker for hepatocellular carcinoma.

本文引用的文献

1
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.随机、多中心前瞻性试验：比较经动脉化疗栓塞（TACE）联合索拉非尼与单纯 TACE 治疗肝细胞癌患者的疗效：TACTICS 试验。
Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4.
基于二硫键化细胞焦亡相关基因构建预后模型并鉴定CCNA2作为肝细胞癌的新型生物标志物
Biol Direct. 2024 Dec 19;19(1):128. doi: 10.1186/s13062-024-00569-9.
4
New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.肝细胞癌局部区域治疗的机制与干预新见解。
Chin J Cancer Res. 2024 Apr 30;36(2):167-194. doi: 10.21147/j.issn.1000-9604.2024.02.06.
5
Plant-derived natural products and combination therapy in liver cancer.植物源天然产物与肝癌的联合治疗
Front Oncol. 2023 Feb 14;13:1116532. doi: 10.3389/fonc.2023.1116532. eCollection 2023.
6
Development of a Model to Predict Liver Decompensation prior to Transarterial Chemoembolization Refractoriness in Patients with Intermediate-Stage Hepatocellular Carcinoma.预测中期肝细胞癌患者经动脉化疗栓塞难治性之前肝失代偿的模型的开发。
GE Port J Gastroenterol. 2021 Nov 30;30(1):29-37. doi: 10.1159/000520530. eCollection 2023 Jan.
7
Increased Liquefactive Necrosis Formation After Transarterial Chemoembolization Combined with Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Hepatocellular Carcinoma.经动脉化疗栓塞联合分子靶向药物及免疫检查点抑制剂治疗肝细胞癌后液化性坏死形成增加
Cancer Manag Res. 2021 Sep 7;13:6935-6941. doi: 10.2147/CMAR.S328812. eCollection 2021.
8
Long Noncoding RNA FOXP4-AS1 Predicts Unfavourable Prognosis and Regulates Proliferation and Invasion in Hepatocellular Carcinoma.长链非编码 RNA FOXP4-AS1 预测肝细胞癌不良预后并调节增殖和侵袭。
Biomed Res Int. 2021 Feb 1;2021:8850656. doi: 10.1155/2021/8850656. eCollection 2021.
9
miR-361-3p Regulates Liver Tumor-initiating Cells Expansion and Chemo-resistance.微小RNA-361-3p调控肝肿瘤起始细胞的扩增及化疗耐药性。
J Cancer. 2021 Jan 1;12(5):1483-1492. doi: 10.7150/jca.52395. eCollection 2021.
10
The Prognostic Significance of miR-21 Expression among Surgically Resected Hepatocellular Carcinoma Patients: Evidence from a Meta-Analysis and Retrospective Cohort Study.手术切除的肝细胞癌患者中 miR-21 表达的预后意义：来自荟萃分析和回顾性队列研究的证据。
Biomed Res Int. 2020 Dec 21;2020:8848158. doi: 10.1155/2020/8848158. eCollection 2020.